SCHEMBL1582340

SCHEMBL1582340

CCOC(=O)/C(=C/CC1CCCC1)c1ccc(SC)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1D1 P20393 1/20 0.41
PKM P14618 1/20 0.40
LIG1 P18858 1/20 0.40
PLAU P00749 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 3/20 0.32
HPGD P15428 2/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
ADORA3 P0DMS8 1/20 0.31
TDP1 Q9NUW8 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HTR1A P08908 1/20 0.30
NR3C1 P04150 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582344 1.00 NR1D1 (0.41) NR1D1PKMLIG1PLAUALDH1A1
SCHEMBL1582342 1.00 NR1D1 (0.41) NR1D1PKMLIG1PLAUALDH1A1
SCHEMBL1582003 0.81 ALDH1A1 (0.34) ALDH1A1L3MBTL1HPGDLMNAPOLB
SCHEMBL1582004 0.81 ALDH1A1 (0.34) ALDH1A1L3MBTL1HPGDLMNAPOLB
SCHEMBL1582006 0.81 ALDH1A1 (0.34) ALDH1A1L3MBTL1HPGDLMNAPOLB
SCHEMBL1581875 0.77 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTLMNAPOLB
SCHEMBL1581872 0.77 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTLMNAPOLB
SCHEMBL1581712 0.73 PKM (0.54) NR1D1PKMLIG1PLAUALDH1A1
SCHEMBL1581391 0.69 KMT2A (0.44) ALDH1A1LMNAPOLBMEN1KMT2A
SCHEMBL1581394 0.69 KMT2A (0.44) ALDH1A1LMNAPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 NR1D1 2147/4885PKM 84/4885LIG1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.